References
- Berg K. A new serum type system in man - the Lp system. Acta Path Microbiol Scand. 1963;59:369–382.
- Kronenberg F, Mora S, Stroes E, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis society consensus statement. Eur Heart J. 2022;43(39):3925–3946. DOI:10.1093/eurheartj/ehac361.
- Mata P, Alonso R, Pérez de Isla L, et al. Dyslipidemia and aortic valve disease. Curr Opin Lipidol. 2021;32(6):349–354.
- Pérez de Isla L, Watts GF, Alonso R, et al. Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia. Eur Heart J. 2021;42(22):2201–2211. DOI:10.1093/eurheartj/ehaa1066
- Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90(1):52–60.
- Tsimikas S, Moriarty P, Stroes E. Emerging RNA therapies to lower blood levels of Lp(a). JACC focus seminar 2/4. J Am Coll Cardiol. 2021;7712:1576–1589. DOI:10.1016/j.jacc.2021.01.051.
- Wilson DP, Jacobson TA, Jones PH, et al. Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13(3):374–392. DOI:10.1016/j.jacl.2019.04.010
- Tsimikas S, Fazio S, Ferdinand K, et al. NHLBI working group recommendations to reduce Lipoprotein(a)- mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol. 2018;71(2):177–192. DOI:10.1016/j.jacc.2017.11.014
- Pearson GJ, Thanassoulis G, Anderson T, et al. Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37(8):1129–1150. DOI:10.1016/j.cjca.2021.03.016
- Arsenault BJ, Kamstrup PR. Lipoprotein(a) and cardiovascular and valvular diseases: a genetic epidemiological perspective. Atherosclerosis. 2022;349:7–16.
- Loh WJ, Chan DC, Mata P, et al. Familial hypercholesterolemia and elevated lipoprotein(a): cascade testing and other implications for contextual models of care. Front Genet. 2020;13:905941.
- Alonso R, Andres E, Mata N, et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol. 2014;63(19):1982–1989. DOI:10.1016/j.jacc.2014.01.063
- Ellis K, Pérez de Isla L, Alonso R, et al. Value of measuring lipoprotein(a)during cascade testing for familial hypercholesterolemia. J Am Coll Cardiol. 2019;739:1029–1039. DOI:10.1016/j.jacc.2018.12.037.
- Chakraborty A, Pang J, Chan D, et al. Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolemia and elevated lipoprotein(a). Atherosclerosis. 2022;349:219–226.
- Chakraborty A, Pang J, Chan D, et al. Cascade testing for elevated lipoprotein(a) in relatives of probands with high lipoprotein(a). Am J Prev Cardiol. 2022;10:100343. DOI:10.1016/j.ajpc.2022.100343.